Prevention of Mother-to-Child Transmission of Viral Infections

Current Problems in Pediatric and Adolescent Health Care

Volumn 38, Issue 9, 2008, Pages 274-297

  Read, Jennifer S ^a   Cannon, Michael J ^b   Stanberry, Lawrence R ^c   Schuval, Susan ^d  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Columbia University ^*  (United States)

^d SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; LAMIVUDINE; MICROBICIDE; NEVIRAPINE; RIBAVIRIN; VALACICLOVIR; VALGANCICLOVIR; VIVAGEL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAPHYLAXIS; ARTICLE; BREAST FEEDING; CARCINOGENESIS; CESAREAN SECTION; CHILD CARE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSAGE SCHEDULE COMPARISON; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEVER; GENITAL HERPES; GONADAL DISEASE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INJECTION SITE PAIN; MOTHER TO CHILD TRANSMISSION; NEUTROPENIA; NEWBORN SCREENING; PATIENT COUNSELING; PATIENT EDUCATION; POLYMERASE CHAIN REACTION; PRENATAL CARE; PREVALENCE; RISK FACTOR; SERODIAGNOSIS; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS INFECTION; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; CESAREAN SECTION; FEMALE; HEPATITIS B; HEPATITIS C; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; IMMUNIZATION; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MILK, HUMAN; PREGNANCY; VIRUS DISEASES;

EID: 52249095728     PISSN: 15385442     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cppeds.2008.08.001     Document Type: Article

References (182)

1. McQuillan G.M., and Kruszon-Moran D. HIV infection in the United States household population aged 18-49 years: results from 1999-2006. NCHS data brief no 4 (2008), National Center for Health Statistics, Hyattsville, MD
2. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2007 AIDS Epidemic Update. Geneva, Switzerland: UNAIDS, 2008. http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive /2007/default.asp (accessibility verified July 14, 2008)
3. Read J.S. Prevention of mother-to-child transmission of HIV. In: Zeichner S.L., and Read J.S. (Eds). Textbook of Pediatric HIV Care (2005), Cambridge University Press, Cambridge, England
4. Cooper E.R., Charurat M., Mofenson L., Hanson I.C., Pitt J., Diaz C., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29 (2002) 484-494
5. Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol 8 (1995) 506-510
6. Kourtis A.P., Bulterys M., Nesheim S.R., and Lee F.K. Understanding the timing of HIV transmission from mother to infant. JAMA 285 (2001) 709-712
7. De Cock K.M., Fowler M.G., Mercier E., de Vincenzi I., Saba J., Hoff E., et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283 9 (2000) 1175-1182
8. Contopoulos-Ioannidis D.G., and Ioannidis J.P.A. Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 18 (1998) 126-135
9. Chuachoowong R., Shaffer N., Siriwasin W., Chaisilwattana P., Young N.L., Mok P.A., et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Infect Dis 181 (2000) 99-106
10. John G.C., Nduati R.W., Mbori-Ngacha D.A., Richardson B.A., Panteleeff D., Mwatha A., et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 182 (2001) 206-212
11. Semba R.D., Kumwenda N., Hoover D.R., Taha T.E., Quinn T.C., Mtimavalye L., et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 180 (1999) 93-98
12. Richardson B., Stewart-John G.C., Hughes J.P., Nduati R., Mbori-Ngacha D., Overbaugh J., et al. Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis 187 (2003) 736-740
13. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies. AIDS 15 (2001) 357-368
14. The Breastfeeding and HIV International Transmission Study (BHITS) Group. Late postnatal transmission of HIV-1 in breastfed children: an individual patient data meta-analysis. J Infect Dis 189 (2004) 2154-2166
15. Coutsoudis A., Pillay K., Kuhn L., Spooner E., Tsai W.Y., and Coovadia H.M. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban. South Africa AIDS 15 (2001) 379-387
16. Iliff P.J., Piwoz E.G., Tavengwa N.V., Iliff P.J., Marinda E.T., Zunguza C.D., et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 19 (2005) 699-708
17. Van de Perre P., Hitimana D.G., Simonon A., Dabis F., Msellati P., Karita P., et al. Postnatal transmission of HIV-1 associated with breast abscess. Lancet 339 (1992) 1490-1491
18. Ekpini E.R., Wiktor S.Z., Satten G.A., Adjorlolo-Johnson G.T., Sibailly T.S., Ou C.Y., et al. Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire. Lancet 349 (1997) 1054-1059
19. Embree J.E., Njenga S., Datta P., Nagelkerke N.J., Ndinya-Achola J.O., Mohammed Z., et al. Risk factors for postnatal mother-child transmission of HIV-1. AIDS 14 (2000) 2535-2541
20. American Academy of Pediatrics. Human immunodeficiency virus infection. In: Pickering L.K., Baker C.J., Long S.S., and McMillan J.A. (Eds). Red Book: 2006 Report of the Committee on Infectious Diseases (2006), American Academy of Pediatrics, Elk Grove Village, IL 378-401
21. Read J.S., and the Committee on Pediatric A.I.D.S. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics 120 6 (2007) e1547-e1562
22. Patel K., Hernan M.A., Williams P.L., Seeger J.D., McIntosh K., Van Dyke R.B., et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 46 (2008) 507-515
23. Connor E.M., Sperling R.S., Gelber R., Kiselev P., Scott G., O'Sullivan M.J., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331 (1994) 1173-1180
24. The European Mode of Delivery Collaboration. Elective caesarean section versus vaginal delivery in preventing vertical HIV-1 transmission: a randomised clinical trial. Lancet 353 (1999) 1035-1037
25. Nduati R., John G., Mbori-Ngacha D., Richardson B., Overbaugh J., Mwatha A., et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 283 (2000) 1167-1174
26. Coovadia H.M., Rollins N.C., Bland R.M., Little K., Coutsoudis A., Bennish M.L., et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 369 (2007) 1107-1116
27. Thior I., Lockman S., Smeaton L.M., Shapiro R.L., Wester C., Heymann S.J., et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: The Mashi Study. JAMA 296 (2006) 794-805
28. Kumwenda N.I., Hoover D.R., Mofenson L.M., Thigpen M.C., Kafulafula G., Li Q., et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 359 (2008) 119-129
29. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 372 9635 (2008) 300-313
30. Centers for Disease Control. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 43 RR11 (1994) 1-20
31. Read J.S. Preventing mother-to-child transmission of HIV: the USA experience. Prenat Neonat Med 4 (1999) 391-397
32. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov (accessibility verified July 14, 2008)
33. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. www.aidsinfo.nih.gov (accessibility verified July 14, 2008)
34. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 340 (1999) 977-987
35. American College of Obstetricians and Gynecologists. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. ACOG Committee Opinion Number 234 (May 2000), ACOG, Washington, D.C.
36. Dominguez K.L., Lindegren M.L., D'Almada P.J., Peters V.B., Frederick T., Rakusan T.A., et al. Increasing trend of cesarean deliveries in HIV-infected women in the United States from 1994 to 2000. J Acquir Immune Defic Syndr 33 (2003) 232-238
37. Centers for Disease Control. Current recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 34 (1985) 721-726
38. American Academy of Pediatrics, Committee on Pediatric AIDS. Human milk, breastfeeding, and transmission of human immunodeficiency virus in the United States. Pediatrics 96 (1995) 977-979
39. Mbori-Ngacha D., Nduati R., John G., Reilly M., Richardson B., Mwatha A., et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: a randomized clinical trial. JAMA 286 (2001) 2413-2420
40. Kuhn L., Aldrovandi G.M., Sinkala M., Kankasa C., Semrau K., Mwiya M., et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 359 (2008) 130-141
41. van der Horst C., Fiscus S., Piwoz E., Corneli A., Moses A., Jones D., et al. Prevention of mother to infant transmission of HIV through breastfeeding and reduction of morbidity and mortality of the breastfeeding mothers: a study in Malawi. Antiviral therapy 8 Suppl 1 (2003) S477
42. de Vincenzi I and the Kesho Bora Study Group. HIV-free survival at 12 months among children born to HIV-infected women receiving antiretrovirals from 34-36 weeks of pregnancy. Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (February 3-6, 2008; Boston, MA) [abstract 638].
43. Orloff S.L., Wallingford J.C., and McDougal J.S. Inactivation of human immunodeficiency virus type 1 in human milk: effects of intrinsic factors in human milk and of pasteurization. J Hum Lact 9 (1993) 13-17
44. Jeffery B.S., Webber L., Mokhondo K.R., and Erasmus D. Determination of the effectiveness of inactivation of human immunodeficiency virus by Pretoria pasteurization. J Trop Pediatr 47 (2001) 345-349
45. Israel-Ballard K., Donovan R., Chantry C., Coutsoudis A., Sheppard H., Sibeko L., et al. Flash-heat inactivation of HIV-1 in human milk. J Acquir Immune Defic Syndr 45 (2007) 318-323
46. Tess B.H., Rodrigues L.C., Newell M.L., Dunn D.T., and Lago T.D. Infant feeding and risk of mother-to-child transmission of HIV-1 in Sao Paulo State. Brazil J Acquir Immune Defic Syndr Hum Retrovirol 19 2 (1998) 189-194
47. Safrit J.T., Ruprecht R., Ferrantelli F., Xu W., Kitabwalla M., Van Rompay K., et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 35 2 (2004) 169-177
48. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mortal Wkly Rep 55 (2006) 1-17 (N0. RR-14)
49. Mofenson L.M., and Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Synd Hum Retrovirol 30 (2002) 200-215
50. Ioannidis J.P., Abrams E.J., Ammann A., Bulterys M., Goedert J.J., Gray L., et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnancy women with RNA virus loads <1000 copies/ml. J Infect Dis 183 (2001) 539-545
51. Shaffer N., Roongpisuthipong A., Siriwasin W., Chotpitayasunondh T., Chearskul S., Young N.L., et al. Maternal viral load and perinatal HIV-1 subtype E transmission. Thailand J Infect Dis 179 (1999) 590-599
52. European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 13 (1999) 1377-1385
53. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 40 3 (2005) 458-465
54. Townsend C.L., Cortina-Borja M., Peckham C.S., de Ruiter A., Lyall H., and Tookey P.A. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22 8 (2008) 971-983
55. Mrus J.M., Goldie S.J., Weinstein M.C., and Tsevat J. The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS 14 (2000) 2543-2552
56. Jamieson D.J., Read J.S., Kourtis A.P., Durant T.M., Lampe M.A., and Dominguez K.L. Cesarean delivery for HIV-infected women: recommendations and controversies. Am J Obstet Gynecol 1997 Suppl 3 (2007) S96-S100
57. Read J.S. Cesarean section delivery to prevent vertical transmission of human immunodeficiency virus type 1: associated risks and other considerations. Ann NY Acad Sci 918 (2000) 115-121
58. Read J.S. Preventing mother to child transmission of HIV: the role of caesarean section. Sex Transm Infect 76 (2000) 231-232
59. Ippolito G., Puro V., Heptonstall J., Jagger J., De Carli G., and Petrosillo N. Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Clin Infect Dis 28 (1999) 365-383
60. Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol 197 2 (2008) 65-73
61. Zhong J., and Khanna R. Vaccine strategies against human cytomegalovirus infection. Exp Rev Anti Infect Ther 5 3 (2007) 449-459
62. Nigro G., Adler S.P., La Torre R., and Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353 13 (2005) 1350-1362
63. American College of Obstetricians and Gynecologists. Perinatal viral and parasitic infections. 20 ed. ACOG Practice Bulletin 20 (2000), ACOG, Washington, DC
64. Barbi M., Binda S., Caroppo S., and Primache V. Neonatal screening for congenital cytomegalovirus infection and hearing loss. J Clin Virol 35 2 (2006) 206-209
65. Kimberlin D.W., Lin C.Y., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 143 1 (2003) 16-25
66. Fowler K.B., Dahle A.J., Boppana S.B., and Pass R.F. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr 135 1 (1999) 60-64
67. Jeon J., Victor M., Adler S.P., Arwady A., Demmler G., Fowler K., et al. Knowledge and awareness of congenital cytomegalovirus among women. Infect Dis Obstet Gynecol 2006 (2006) 1-7
68. Ross D.S., Victor M., Sumartojo E., and Cannon M.J. Women's knowledge of congenital cytomegalovirus: results from the 2005 HealthStyles™ survey. J Womens Health (Larchmt) 17 5 (2008) 849-858
69. Revello M.G., and Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15 4 (2002) 680-715
70. Kenneson A., and Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17 4 (2007) 253-276
71. Dollard S.C., Grosse S.D., and Ross D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17 5 (2007) 355-363
72. Cannon M.J., and Davis K.F. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 5 1 (2005) 70
73. Stagno S. Cytomegalovirus. In: Remington J.S., and Klein J.O. (Eds). Infectious diseases of the fetus and newborn infant (2001), W.B. Saunders, Philadelphia (PA) 389-424
74. Hamprecht K., Maschmann J., Jahn G., Poets C.F., and Goelz R. Cytomegalovirus transmission to preterm infants during lactation. J Clin Virol 41 3 (2008) 198-205
75. Pass R.F., Hutto C., Ricks R., and Cloud G.A. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J Med 314 22 (1986) 1414-1418
76. Fowler K.B., and Pass R.F. Risk factors for congenital cytomegalovirus infection in the offspring of young women: exposure to young children and recent onset of sexual activity. Pediatrics 118 2 (2006) e286-e292
77. Staras S.A., Flanders W.D., Dollard S.C., Pass R.F., McGowan Jr. J.E., and Cannon M.J. Influence of sexual activity on cytomegalovirus seroprevalence in the United States, 1988-1994. Sex Transm Dis 35 5 (2008) 472-479
78. Staras S.A.S., Dollard S.C., Radford K.W., Flanders W.D., Pass R.F., and Cannon M.J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43 (2006) 1143-1151
79. Colugnati F.A., Staras S.A., Dollard S.C., and Cannon M.J. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis 7 (2007) 71
80. Boppana S.B., Fowler K.B., Britt W.J., Stagno S., and Pass R.F. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104 1 Pt. 1 (1999) 55-60
81. Boppana S.B., Pass R.F., Britt W.J., Stagno S., and Alford C.A. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 11 2 (1992) 93-99
82. Barbi M., MacKay W.G., Binda S., and van Loon A.M. External quality assessment of cytomegalovirus DNA detection on dried blood spots. BMC Microbiol 8 (2008) 2
83. Boppana S.B., Smith R.J., Stagno S., and Britt W.J. Evaluation of a microtiter plate fluorescent-antibody assay for rapid detection of human cytomegalovirus infection. J Clin Microbiol 30 3 (1992) 721-723
84. Kimberlin D.W., Acosta E.P., Sanchez P.J., Sood S., Agrawal V., Homans J., et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 197 6 (2008) 836-845
85. American Academy of Pediatrics. Cytomegalovirus Infection. In: Pickering L.K., Baker C.J., Long S.S., and McMillan J.A. (Eds). Red Book: 2006 Report of the Committee on Infectious Diseases (2006), American Academy of Pediatrics, Elk Grove Village, IL 273-276
86. Smets K., De Coen K., Dhooge I., Standaert L., Laroche S., Mahiew L., et al. Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy. Eur J Pediatr 165 12 (2006) 885-890
87. Luck S., Sharland M., and Griffiths P. Ganciclovir therapy for neonates with congenital cytomegalovirus infection. Eur J Pediatr 166 6 (2007) 633-634
88. Michaels M.G. Treatment of congenital cytomegalovirus: where are we now?. Exp Rev Anti Infect Ther 5 3 (2007) 441-448
89. Centers for Disease Control and Prevention. Knowledge and practices of obstetricians and gynecologists regarding cytomegalovirus infection during pregnancy-United States, 2007. MMWR Morb Mortal Wkly Rep 57 3 (2008) 65-68
90. Istas A.S., Demmler G.J., Dobbins J.G., and Stewart J.A. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 20 3 (1995) 665-670
91. Sharon B., and Schleiss M.R. Congenital cytomegalovirus infection: an unrecognized epidemic. Infect Med 24 (2007) 402-415
92. Kemper A.R., Uren R.L., Moseley K.L., and Clark S.J. Primary care physicians' attitudes regarding follow-up care for children with positive newborn screening results. Pediatrics 118 5 (2006) 1836-1841
93. Rietmeijer C.A. Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work. Sex Transm Infect 83 1 (2007) 2-9
94. Kreuter M.W., Chheda S.G., and Bull F.C. How does physician advice influence patient behavior?. Evidence for a priming effect. Arch Fam Med 9 5 (2000) 426-433
95. Ross D.S., Dollard S.C., Victor M., Sumartojo E., and Cannon M.J. The epidemiology and prevention of congenital cytomegalovirus infection and disease: activities of the Centers for Disease Control and Prevention Workgroup. J Womens Health (Larchmt) 15 3 (2006) 224-229
96. Morton C.C., and Nance W.E. Newborn hearing screening-a silent revolution. N Engl J Med 354 20 (2006) 2151-2164
97. Adler S.P. Congenital cytomegalovirus screening. Pediatr Infect Dis J 24 12 (2005) 1105-1106
98. Bailey Jr. D.B., Armstrong F.D., Kemper A.R., Skinner D., and Warren S.F. Supporting family adaptation to presymptomatic and "untreatable" conditions in an era of expanded newborn screening. J Pediatr Psychol (2008) (in press)
99. Fowler K.B., McCollister F.P., Dahle A.J., Boppana S., Britt W.J., and Pass R.F. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 130 4 (1997) 624-630
100. Rivera L.B., Boppana S.B., Fowler K.B., Britt W.J., Stagno S., and Pass R.F. Predictors of hearing loss in children with symptomatic congenital cytomegalovirus. Pediatrics 110 4 (2002) 762-767
101. Boppana S.B., Fowler K.B., Pass R.F., Rivera L.B., Bradford R.D., Lakeman F.D., et al. Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J Pediatr 146 6 (2005) 817-823
102. Lanari M., Lazzarotto T., Venturi V., Papa I., Gabrielli L., Guerra B., et al. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics 117 1 (2006) e76-e83
103. Noyola D.E., Demmler G.J., Nelson C.T., Griesser C., Williamson W.D., Atkins J.T., et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr 138 3 (2001) 325-331
104. Ancora G., Lanari M., Lazzarotto T., Venturi V., Tridapalli E., Sandri F., et al. Cranial ultrasound scanning and prediction of outcome in newborns with congenital cytomegalovirus infection. J Pediatr 150 2 (2007) 157-161
105. Boppana S.B., Fowler K.B., Vaid Y., Hedlund G., Stagno S., Britt W.J., et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 99 3 (1997) 409-414
106. Guralnick M.J. Effectiveness of early intervention for vulnerable children: a developmental perspective. Am J Ment Retard 102 4 (1998) 319-345
107. Bailey Jr. D.B., Skinner D., Davis A.M., Whitmarsh I., and Powell C. Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues. Pediatrics 121 3 (2008) e693-e704
108. Yoshinaga-Itano C. Early intervention after universal neonatal hearing screening: impact on outcomes. Ment Retard Dev Disabil Res Rev 9 4 (2003) 252-266
109. Walker S.P., Chang S.M., Powell C.A., and Grantham-McGregor S.M. Effects of early childhood psychosocial stimulation and nutritional supplementation on cognition and education in growth-stunted Jamaican children: prospective cohort study. Lancet 366 9499 (2005) 1804-1807
110. Brown E.L., Gardella C., Malm G., Prober C.G., Forsgren M., Krantz E.M., et al. Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Acta Obstet Gynecol Scand 86 (2007) 523-529
111. Handsfield H.H., Waldo A.B., Brown Z.A., Corey L., Drucker J.L., Ebel C.W., et al. Neonatal herpes should be a reportable disease. Sex Transm Dis 32 (2005) 521-525
112. Whitley R.J. Neonatal herpes simplex virus infections. J Med Virol Suppl 1 (1993) 13-21
113. Dinh T.H., Dunne E.F., Markowitz L.E., Weinstock H., and Berman S. Assessing neonatal herpes reporting in the United States, 2000-2005. Sex Transm Dis 35 (2008) 19-21
114. Xu F., Sternberg M.R., Kottiri B.J., McQuillan G.M., Lee F.K., Nahmias A.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296 (2006) 964-973
115. Brown Z. Preventing herpes simplex virus transmission to the neonate. Herpes 11 Suppl 3 (2004) 175A-186A
116. Brown Z.A., Selke S., Zeh J., Kopelman J., Maslow A., Ashley R.L., et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 337 (1997) 509-515
117. Brown E.L., Morrow R., Krantz E.M., Arvin A.M., Prober C.G., Yasukawa L.L., et al. Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol 195 (2006) 115-120
118. Kimberlin D.W. Herpes simplex virus infections of the newborn. Semin Perinatol 31 (2007) 19-25
119. Enright A.M., and Prober C.G. Herpesviridae infections in newborns: varicella zoster virus, herpes simplex virus, and cytomegalovirus. Pediatr Clin North Am 51 (2004) 889-908
120. Kimberlin D.W., Lin C.Y., Jacobs R.F., Powell D.A., Corey L., Gruber W.C., et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108 (2001) 230-238
121. Englund J.A., Fletcher C.V., and Balfour Jr. H.H. Acyclovir therapy in neonates. J Pediatr 119 (1991) 129-135
122. Brown Z.A., Wald A., Morrow R.A., Selke S., Zeh J., and Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 289 (2003) 203-209
123. Sullivan-Bolyai J.Z., Hull H.F., Wilson C., Smith A.L., and Corey L. Presentation of neonatal herpes simplex virus infections: implications for a change in therapeutic strategy. Pediatr Infect Dis 5 (1986) 309-314
124. Stone K.M., Brooks C.A., Guinan M.E., and Alexander E.R. National surveillance for neonatal herpes simplex virus infections. Sex Transm Dis 16 (1989) 152-156
125. Roberts S.W., Cox S.M., Dax J., Wendel Jr. G.D., and Leveno K.J. Genital herpes during pregnancy: no lesions, no cesarean. Obstet Gynecol 85 (1995) 261-264
126. Randolph A.G., Washington A.E., and Prober C.G. Cesarean delivery for women presenting with genital herpes lesions. Efficacy, risks, and costs. JAMA 270 (1993) 77-82
127. Nilsen A.E., Aasen T., Halsos A.M., Kinge B.R., Tjotta E.A., Wikstrom K., et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 2 (1982) 571-573
128. Reichman R.C., Badger G.J., Mertz G.J., Corey L., Richman D.D., Connor J.D., et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 251 (1984) 2103-2107
129. Wald A., Zeh J., Barnum G., Davis L.G., and Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 124 (1996) 8-15
130. Reitano M., Tyring S., Lang W., Thoming C., Worm A.M., Borelli S., et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 178 (1998) 603-610
131. Diaz-Mitoma F., Sibbald R.G., Shafran S.D., Boon R., and Saltzman R.L. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA 280 (1998) 887-892
132. Wittek A.E., Yeager A.S., Au D.S., and Hensleigh P.A. Asymptomatic shedding of herpes simplex virus from the cervix and lesion site during pregnancy. Am J Dis Child 138 (1984) 439-442
133. Simkovich J.W., and Soper D.E. Asymptomatic shedding of herpes virus during labor. Am J Obstet Gynecol 158 (1988) 588-589
134. Yeager A.S., and Arvin A.M. Reasons for the absence of a history of recurrent genital herpes infections in mothers of neonates infected with herpes simplex virus. Pediatrics 73 (1984) 188-193
135. Brown Z.A., Benedetti J., Ashley R., Burchett S., Selke S., Berry S., et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 324 (1991) 1247-1252
136. Hollier L., and Wendel G. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev 23 (2008) CD004946
137. ACOG Practice Bulletin No. 8. Management of herpes in pregnancy. 1999. Int J Gynaecol Obstet 68 (2000) 165-173
138. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350 (2004) 11-20
139. Kinghorn G.R. Debate: the argument for. Should all pregnant women be offered type-specific serological screening for HSV infection?. Herpes 9 (2002) 46-47
140. Arvin A.M. Debate: the argument against. Should all pregnant women be offered type-specific serological screening for HSV infection?. Herpes 9 (2002) 48-50
141. Urato A.C., and Caughey A.B. Universal prenatal herpes screening is a bad idea in pregnancy. Lancet 368 (2006) 898-899
142. Tita A.T., Grobman W.A., and Rouse D.J. Antenatal herpes serological screening: an appraisal of the evidence. Obstet Gynecol 108 (2006) 1247-1253
143. Robinson J.L., Lee B.E., Preiksaitis J.K., Plitt S., and Tipples G.A. Prevention of congenital rubella syndrome-what makes sense in 2006?. Epidemiol Rev 28 (2006) 81-87
144. Stanberry L., Cunningham A., Mindel A., Scott L., Spruance S., Aoki F., et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 30 (2000) 549-566
145. Jones C.A., and Cunningham A.L. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 11 (2004) 12-17
146. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347 (2002) 1652-1661
147. Garnett G.P., Dubin G., Slaoui M., and Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 80 (2004) 24-29
148. Bravo F.J., Bourne N., Harrison C.J., Mani C., Stanberry L.R., Myers M.G., et al. Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. J Infect Dis 173 (1996) 1-6
149. Rosenthal S.L., Cohen S.S., and Stanberry L.R. Topical microbicides. Current status and research considerations for adolescent girls. Sex Transm Dis 25 (1998) 368-377
150. Keller M.J., Tuyama A., Carlucci M.J., and Herold B.C. Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 55 (2005) 420-423
151. Rupp R., Rosenthal S.L., and Stanberry L.R. VivaGel™ (SPL7013 Gel): A candidate dendrimer- microbicide for the prevention of HIV and HSV infection. Int J Nanomed 2 (2007) 561-566
152. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin Liver Dis 25 (2005) 3-8
153. Lavanchy D. Hepatitis B virus epidemiology, disease, burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
154. Davis A.R., and Rosenthal P. Hepatitis B in children. Pediatr Rev 29 (2008) 111-120
155. Elisofon S.A., and Jonas M.M. Hepatitis B and C in children: current treatment and future strategies. Clin Liver Dis 10 (2006) 133-148
156. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States-recommendations of the ACIP. Part 1: immunization of infants, children, and adolescents. MMWR Morb Mortal Wkly Rep 54 (2005) (No. RR-16)
157. Shepard C.W., Simard E.P., Finelli L., Fiore A.E., and Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28 (2006) 112-125
158. Mahoney F.J. Update on diagnosis, management, and prevention of hepatitis B virus infections. Clin Microbiol Rev 12 (1999) 351-366
159. Tong M.J., Thursby M., Rakela J., McPeak C., Edwards V.M., and Mosley J.W. Studies on the maternal-infant transmission of the viruses which cause acute hepatitis. Gastroenterology 80 (1981) 999-1004
160. Stevens C.E., Neurath R.A., Beasley R.P., and Szmuness W. HBeAg and anti-HBe detection with radio-immunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 3 (1979) 237-241
161. American Academy of Pediatrics. Hepatitis B. In: Pickering LK, editor. American Academy of Pediatrics Red Book: 2006 Report of the Committee on Infectious Diseases. 27th edition. Elk Grove Village, IL: 2006, p. 335-55.
162. Shneider B.L., Gonzalez-Peralta R., and Roberts E.A. Controversies in the management of pediatric liver disease: Hepatitis B, C, and NAFLD: summary of a single topic conference. Hepatology 44 (2006) 1344-1354
163. Chang M.H., Sung J.L., Lee C.Y., Chen C.J., Chen J.S., Hsu H.Y., et al. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr 115 (1989) 385-390
164. Bortolotti F., Guido M., Bartolacci S., Cadrobbi P., Crivellaro C., Noventa F., et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 43 (2006) 556-562
165. Chen C.H., Chen Y.Y., Chen G.H., Yang S.S., Tang H.S., Lin H.H., et al. Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13,676 relatives with hepatocellular carcinoma. J Hepatol 40 (2004) 653-659
166. Centers for Disease Control and Prevention. A comprehensive immunization
167. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis-United States 2006. MMWR Morb Mortal Wkly Rep 57 (2008) (No. SS-2)
168. World Health Organization. 2005 Global Immunization Data (2006), WHO, Geneva, Switzerland. http://www.who.int/immunization_monitoring/data/GlobalImmunizationData.p df
169. Hadzic N. Hepatitis C in pregnancy. Arch Dis Child Fetal Neonatal Ed 84 (2001) F201-F204
170. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
171. Davison S.M., Mieli-Vergani G., Sira J., and Kelly D.A. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Childhood 91 (2006) 781-785
172. American Academy of Pediatrics. Hepatitis C. In: Pickering LK, editor. American Academy of Pediatrics Red Book: 2006 Report of the Committee on Infectious Diseases. 27th edition. Elk Grove Village, IL: 2006. p. 355-9.
173. Roberts E.A., and Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 36 (2002) S106-S113
174. European Paediatric Hepatitis Virus C Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 41 (2005) 45-51
175. Mast E.E., Hwang L.Y., Seto D.S.Y., Nolte F.S., Nainan O.V., Wurtzel H., et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 192 (2005) 2880-2889
176. Mok J., Pembrey L., Tovo P.A., and Newell M.L. When does mother to child transmission of hepatitis C virus occur?. Arch Dis Child Fetal Neonatal Ed 90 (2005) F156-F160
177. Shiraki K., Ohto H., Inaba N., Fujisawa T., Tajiri H., Kanzaki S., et al. Guidelines for care of pregnant women carrying hepatitis C virus and their infants. Pediatr Int 50 (2008) 138-140
178. European Paediatric Hepatitis Virus C Network. A significant sex- but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 192 (2005) 1872-1879
179. Bortolotti F., Resti M., Marcellini M., Giacchino R., Verucchi G., Nebbia G., et al. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut 54 (2005) 852-857
180. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatol 39 (2004) 1147-1166
181. Mohan P., Colvin C., Glymph C., Chandra R.R., Kleiner D.E., Patel K.M., et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 150 (2007) 168-174
182. Centers for Disease Control and Prevention. Recommendations for the prevention and control of hepatitis C virus infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 47 (1998) (No. RR-19)